Compare Abbott Laboratories (ABT) vs Autozone Inc (AZO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Autozone Inc — how do they compare? Abbott Laboratories trades at $109.8 (market cap $187.95B), while Autozone Inc trades at $3,025.08 (market cap $50.09B). The key difference: Abbott Laboratories is far larger — about 3.8× Autozone Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Autozone Inc pays none. Which is the better fit depends on your goals.
| ABT | AZO | |
|---|---|---|
Market Cap | $187.95B | $50.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $4.35K |
52-Week Low | $82.57 | $2.92K |
Enterprise Value | $214.96B | $62.46B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
AutoZone (AZO) trades at $3,127.29, up 1.88% recently, with a bullish technical signal and strong analyst support. Revenue grew to $18.94B in 2025, though net income margin dipped to 13.19%. The company maintains robust cash flow from operations and recently authorized a $1.5B stock buyback, signaling confidence. Key resistance lies near $3,160, with support at $3,063.
Outlook remains positive with 73% analyst buy ratings and a $3,730 consensus price target, implying ~19% upside. Risks include margin pressure from rising costs and competitive threats. Earnings beats in recent quarters support growth, but investors should monitor execution on international expansion and capex efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
